Baxter (NYSE: BAX) + announced today that it picked “Vantive” as the name of its proposed kidney care spinoff.
In January, Baxter announced plans to spin its renal care and acute therapies units into an independent, publicly traded company. It said at the time that it expected the company to stand alone in the next 12 to 18 months. Baxter said today that it expects Vantive to launch as an independent, publicly traded company by July 2024 or earlier.
The company picked Chris Toth, EVP and group president, kidney care, to serve as CEO of the new company upon the spinoff’s completion.
“Announcing the Vantive name is a critical milestone in our journey to becoming an independent company focused solely on therapies for kidney disease and other vital organ support,” said Toth “The Vantive name reflects our dedicated employees’ steadfast commitment to patients and our passion for helping them lead ful…